Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3.18 USD | -.--% | -7.56% | +114.86% |
May. 02 | Transcript : Cardiff Oncology, Inc., Q1 2024 Earnings Call, May 02, 2024 | |
May. 02 | Cardiff Oncology, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Financials (USD)
Sales 2024 * | 390K | Sales 2025 * | 66.67K | Capitalization | 142M |
---|---|---|---|---|---|
Net income 2024 * | -45M | Net income 2025 * | -57M | EV / Sales 2024 * | 365 x |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 2,133 x |
P/E ratio 2024 * |
-3.25
x | P/E ratio 2025 * |
-3
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 92.33% |
Latest transcript on Cardiff Oncology, Inc.
1 week | -7.56% | ||
1 month | -27.06% | ||
3 months | +80.17% | ||
6 months | +158.54% | ||
Current year | +114.86% |
Managers | Title | Age | Since |
---|---|---|---|
Mark Erlander
CEO | Chief Executive Officer | 64 | 13-03-03 |
James Levine
DFI | Director of Finance/CFO | 53 | 21-07-11 |
Tod Smeal
CTO | Chief Tech/Sci/R&D Officer | 59 | 22-01-10 |
Members of the board | Title | Age | Since |
---|---|---|---|
James Armitage
BRD | Director/Board Member | 77 | 20-04-21 |
Gary Pace
BRD | Director/Board Member | 76 | 20-04-21 |
Mark Erlander
CEO | Chief Executive Officer | 64 | 13-03-03 |
Date | Price | Change | Volume |
---|---|---|---|
24-05-31 | 3.18 | -.--% | 180,192 |
24-05-30 | 3.18 | -0.63% | 266,757 |
24-05-29 | 3.2 | -1.54% | 251,528 |
24-05-28 | 3.25 | -5.52% | 670,535 |
24-05-24 | 3.44 | +4.24% | 398,929 |
Delayed Quote Nasdaq, May 31, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+114.86% | 142M | |
+43.36% | 58.06B | |
-5.31% | 40.53B | |
+37.52% | 38.99B | |
+14.75% | 26.7B | |
-12.56% | 26.56B | |
-22.45% | 18.98B | |
+0.04% | 12.17B | |
+25.12% | 12B | |
+26.04% | 11.92B |
- Stock Market
- Equities
- CRDF Stock